---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124598"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:50.082558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q3 net loss $15M; cash $80.5M; amends AstraZeneca deal with $114.3M milestone potential

## Summary
- Amended AstraZeneca license agreement modifies development milestones; potential future payments up to $114.3M in cash and ADSs; issued 2.04M shares and paid $0.5M.
- Q3 net loss $15.0M vs $6.5M YoY, driven by $6.4M foreign exchange loss; R&D down 12% to $3.2M.
- Cash $80.5M as of Sep 30, 2024 (up from $57.4M Dec 2023); expected to fund operations into 2027.
- Setrusumab received FDA Breakthrough Therapy designation for osteogenesis imperfecta; Phase 3 topline data expected 2025.
- Alvelestat remains on track to be Phase 3-ready by end of 2024; partnership discussions ongoing.

## SEC filing metadata
- accession: 0000950170-24-124598
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/0000950170-24-124598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/mreo-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124598
- JSON: https://secwatch.observer/filing/0000950170-24-124598.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.